Abstract： Objective To evaluate the efficacy in the treatment of age-related macular degeneration (AMD) by bevacizumab versus ranibizumab.Methods A computerized search was conducted in the Embase,Ovid,PubMed,China National Knowledge Infrastructure (CNKI),WanFang Data and VIP database of Chinese journal.Randomized controlled trials (RCTs) comparing bevacizumab with ranibizumab for AMD from inception to November,2013 were collected.Methodology qualifies of studies were performed by experienced reviewers according to the inclusion and exclusion criteria.Further,the materials were analyzed with software RevMan 5.2.6.Visual acuity and central foveal thickness before and 3,6,12 months after treatment between the two treatment methods were compared.Results A total of 5 RCTs were included in this meta analysis,including 1954 patients (967 patients in the bevacizumab group,987 eyes in the ranibizumab group).There was no difference in improving visual acuity after treatment between two groups [3 months:weighted mean difference (WMD) =0.32,95％ CI:-0.84-1.49,P=0.59;6 months:WMD=0.47,95％ CI:-0.67-1.62,P=0.42; 12 months:WMD=0.84,95％ CI:-0.23-1.90,P=0.12].There was no difference in cutting down the central foveal thickness after treatment between two groups (3 months:WMD=6.21,95％ CI:-6.23-18.65,P=0.33; 6 months:WMD=4.06,95％ CI:-6.16-14.27,P=0.44; 12 months:WMD=-5.39,95％ CI:-14.41-3.63,P=0.24).Conclusion Bevacizumab has equal efficacy to ranibizumab in the treatment of AMD.